Clinical Trials
4
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (100.0%)A Study of KD6005 in Healthy Participants and Participants With Rheumatoid Arthritis (RA)
- First Posted Date
- 2024-01-19
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Shanghai Kanda Biotechnology Co., Ltd.
- Target Recruit Count
- 72
- Registration Number
- NCT06213259
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, China
KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors
Phase 1
Not yet recruiting
- Conditions
- Advanced HCCOther Solid Tumors
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Shanghai Kanda Biotechnology Co., Ltd.
- Target Recruit Count
- 85
- Registration Number
- NCT05906524
- Locations
- 🇨🇳
Zhongshan Hospital, Shanghai, China
KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma
- First Posted Date
- 2023-02-10
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- Shanghai Kanda Biotechnology Co., Ltd.
- Target Recruit Count
- 84
- Registration Number
- NCT05723432
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
Clinical Study of KD6001 in Advanced Solid Tumours
Phase 1
Completed
- Conditions
- Solid Tumor
- First Posted Date
- 2022-02-08
- Last Posted Date
- 2023-02-06
- Lead Sponsor
- Shanghai Kanda Biotechnology Co., Ltd.
- Target Recruit Count
- 13
- Registration Number
- NCT05230290
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
News
No news found